15
Jul
2019
Tag: immunotherapy
15
Apr
2019
Bionest
Bifunctional Antibodies: The Next Generation of Immuno-oncology Agents
Immuno-oncology agents, particularly checkpoint inhibitors, have moved to the forefront of cancer research and treatment in recent years. Indeed, the discovery that cancer could be treated by activating the immune system was honored with a Nobel Prize in 2018. But, as revolutionary as immuno-oncology drugs have been for the cancer field, many patients still do...
4
Mar
2019
Bionest
Targeting Brain Cancer with New Vaccine Approaches
Glioblastoma multiforme (GBM) is the most common form of brain cancer affecting adults. It is also one of the deadliest and hardest to treat cancers. About half of all people with GBM survive longer than 18 months, but only 15% are still alive five years post diagnosis. Of the approximately two dozen experimental treatments tested...
3
Dec
2018
Bionest
Report on ESMO 2018 – Part One
We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings, plus plenty of positive data from a variety of combination therapy trials in breast cancer, including triple-negative breast cancer. (Neo)Adjuvant Treatment Gets a Boost ...
4
Oct
2018
Bionest
Seminal Immuno-oncology Discoveries Honored by 2018 Nobel Prize
Seemingly spontaneous remissions from terminal cancers are known to occur on rare occasions. For over 100 years, this observation has spurred scientists to attempt to engage the immune system to fight cancer, with little success. But on October 1, the 2018 Nobel Prize in physiology and medicine was awarded to two scientists whose seminal discoveries...
21
May
2018
Bionest
Anticipating ASCO
We always greatly anticipate the scientific and educational sessions presented at the American Society of Clinical Oncology (ASCO) annual meeting, this year being held in Chicago from June 1-5. The meeting is the largest of its kind focused on cancer, attracting more than 30,000 oncology professionals from around the world to discuss ”state-of-the-art treatment modalities, new therapies,...
14
May
2018
Bionest
New Gains in Frontline Non-Small Cell Lung Cancer
Each spring, those of us who watch the oncology space turn our attention to two big U.S. meetings for the latest research news: the American Association of Cancer Research (AACR) annual scientific meeting, held in April, and the American Society of Clinical Oncology (ASCO), which will take place in June. AACR previously focused primarily on...
7
May
2018
Bionest
New Contender in Race to Develop Allogeneic CAR-T Treatments
Just months after negotiating the sale of autologous CAR-T pioneer Kite Pharma to Gilead for $11.9 billion, two of the executives who led Kite to success are back with a new company, a clinical-stage asset, and a portfolio of 16 preclinical therapeutic candidates, as well as substantial financing. This time, the focus is the development...
17
Apr
2018
Bionest
Moving from Exploratory Collaborations to Record-Setting Deals in IO
In early March, we wrote about the collaboration between Bristol-Myers Squibb and Nektar aimed at developing Nektar’s T-cell stimulating molecule NKTR-214 in combination with BMS’s checkpoint inhibitor Opdivo (nivolumab). That deal brought Nektar an eye-opening $1.85 billion in upfront cash and investments for a share of its development-stage drug, with the potential for an additional...
6
Mar
2018